ATLANTA, Jan. 13, 2014 /PRNewswire/
-- EndoChoice® has added two highly regarded
business leaders to the board of directors. Mr. Scott Davis, the Chairman and CEO of UPS (NYSE:
UPS) and Mr. Scott Huennekens,
President and CEO of Volcano Corporation (NASDAQ: VOLC) have joined
the board as EndoChoice looks to more than double its revenue in
2014.
"I have been watching EndoChoice grow for the last several
years," said Davis. "The emphasis on innovation, quality execution
and growth has helped EndoChoice become one of the most dynamic
players in the medical technology industry. The future for
EndoChoice is very bright."
UPS and EndoChoice have been working together to deliver
EndoChoice's proprietary products and services to hospitals,
ambulatory surgery centers and physician offices around the
world.
"You can count on one hand the number of medtech companies over
$50 million that are growing more
than 30% in 2014. There is only one with which I'm familiar
that is going to grow at greater than 100%," said Huennekens.
"Opportunities to help guide companies on this growth trajectory
are rare; I'm excited to be involved with EndoChoice."
EndoChoice is the fastest growing company in the video endoscopy
market with the launch of the Fuse™ Full Spectrum Endoscopy™
system, the first and only endoscope with multiple imagers
providing endoscopists the potential to diagnose and treat more
diseases of the gastrointestinal tract.
About EndoChoice
Based in Atlanta, EndoChoice is
a medtech company focused on the manufacturing and
commercialization of platform technologies including devices,
diagnostics, infection control and endoscopic imaging for
specialists treating a wide range of gastrointestinal (GI)
diseases. EndoChoice leverages its direct sales organization
to serve more than 2,000 customers in the
United States and works with 34 distribution partners
world-wide. The Company was founded in 2008 and has rapidly
developed a proprietary product portfolio, which includes the
revolutionary Full Spectrum Endoscopy™ System (Fuse™). The
Fuse System is comprised of colonoscopes and gastroscopes with
multiple imagers so doctors can see more of the GI tract for
diagnosis and treatment. The Fuse colonoscope provides a
field of view of 330 degrees versus 170 degrees from traditional
endoscopes. In clinical studies, Fuse found 70% more polyps
than traditional colonoscopes. 2013 marked the fourth
consecutive year EndoChoice was recognized as one of the fastest
growing companies in the U.S. by Inc. Magazine. To
learn more, visit www.endochoice.com
EndoChoice® and Fuse™ are trademarks of EndoChoice®, Inc.
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or Doug.Ladd@endochoice.com
SOURCE EndoChoice